

BERK BERNARD  
Form 4  
September 07, 2005

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
BERK BERNARD

2. Issuer Name and Ticker or Trading Symbol  
ELITE PHARMACEUTICALS INC  
/DE/ [ELI]

5. Relationship of Reporting Person(s) to Issuer  
  
(Check all applicable)

(Last) (First) (Middle)  
C/O ELITE PHARMACEUTICALS,  
INC., 165 LUDLOW AVENUE  
  
(Street)

3. Date of Earliest Transaction  
(Month/Day/Year)  
09/02/2005

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
Chief Exec Officer & Chairman

NORTHVALE, NJ 06830

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership Indirect Beneficial Ownership (Instr. 4)
				(A) or (D)	Code V Amount (D) Price		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transaction	5. Number of Derivative Securities	6. Date Exercisable and Expiration Date	7. Title and Amount of Underlying Security
------------------------	---------------	--------------------------------------	-------------------------------	----------------	------------------------------------	---	--

Edgar Filing: BERK BERNARD - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security	any (Month/Day/Year)	Code (Instr. 8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/Year)	(Instr. 3 and 4)		
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Am Num Sha
Option	\$ 2.69	09/02/2005	A	200,000	(1)	09/02/2015	Common Stock	90
Option	\$ 2.69	09/02/2005	A	400,000	(2)	09/02/2015	Common Stock	40
Option	\$ 2.15	06/23/2003	J	\$ 75,000 (3)	09/02/2005	06/22/2013	Common Stock	22

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
BERK BERNARD C/O ELITE PHARMACEUTICALS, INC. 165 LUDLOW AVENUE NORTHVALE, NJ 06830	X		Chief Exec Officer & Chairman	

## Signatures

/s/ Bernard J. Berk  
09/02/2005

\*\*Signature of Reporting Person Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) 100,000 of the options shall vest on September 2, 2006 and 100,000 of the options shall vest on September 2, 2007.

The options vest as follows: (i) 50,000 options upon the closing of each product license or product sale transaction (on a product by product basis and only once for each product) in which the Registrant receives an aggregate of at least \$5,000,000 in net cash proceeds (including royalties and signing, license and milestone payments) in connection with such product transaction; (ii) 10,000 options upon the filing by the Registrant (in the Registrant's name) with the United States Food and Drug Administration (the "FDA") of either an Abbreviated New Drug Application ("ANDA") or New Drug Application (including 505(b)(2) applications) ("NDA") for a product not covered by a previous FDA application; and (iii) 40,000 options s upon the approval by the FDA of any ANDA or NDA of the Registrant (filed in the Registrant's name) for a product not previously approved by the FDA; provided however, that on September 2, 2009 all unvested options shall terminate.

The Reporting Person was granted 300,000 options of the Registrant on July 23, 2003 which would vest upon a Strategic Transaction.  
(3) The Registrant determined that a Strategic Transaction has occurred as of September 2, 2005. Furthermore, in connection with entering into an amended and restated employment agreement, the Reporting Person waived rights to 75,000 options.

(4) In addition to the transactions described above, this amount also includes options to purchase 300,000 shares of common stock but does not include 167,300 shares of Common Stock beneficially owned by the Reporting Person.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

## Edgar Filing: BERK BERNARD - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.